Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160

Y. Qin, Andrew V Schally, G. Willems

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Hepatic metastases of colon 320 DM and WidR human colon cancers in nude mice were treated by s.c. injections of somatostatin analogue RC-160 for 4 weeks. Chronic administration of RC-160 significantly inhibited the incidence and growth of liver metastases of these 2 colon-cancer cell lines. After RC-160 treatment, the incidence of liver metastases decreased by 25% for colon 320 DM cells and by 37.5% for WidR cells. The mean number of metastatic tumors in each liver decreased by 47.9% for colon 320 DM and 42.6% for WidR. Survival times of mice with liver tumors of colon 320 DM and WidR cells were prolonged by 20 days and 7 days, respectively. The inhibitory effect of RC-160 on the growth of these 2 colon cancers implanted s.c. was also observed. After administration of RC160 for 4 weeks, the mean tumor volume in the treated groups was only 39.8% of that of controls for the colon 320 DM line and 58% for the WidR line. Tumor-growth rate and final tumor weight were also significantly decreased, while tumor-volume doubling time and tumor-growth delay time were prolonged. The effect of RC-160 on cellular proliferation in the tumors was studied by in vivo labelling with bromodeoxyuridine and immunoperoxidase staining. The mean labelling index in the treatment group was reduced by 14.9% and 19.5%, respectively, for colon 320 DM and WidR tumors. The cytostatic effect of RC-160 was also evident from the apparent reduction in DNA and protein content in the tumor tissues of these cancer lines. Our findings suggest that somatostatin analogue RC-160 may be useful for the treatment of patients with hepatic metastases of colon cancer.

Original languageEnglish
Pages (from-to)791-796
Number of pages6
JournalInternational Journal of Cancer
Volume52
Issue number5
DOIs
StatePublished - Nov 27 1992
Externally publishedYes

Fingerprint

Somatostatin
Nude Mice
Colonic Neoplasms
Neoplasm Metastasis
Colon
Liver
Neoplasms
Tumor Burden
Therapeutics
Growth
vapreotide
Incidence
Cytostatic Agents
Bromodeoxyuridine
Cell Proliferation
Staining and Labeling
Cell Line
Injections
Survival
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. / Qin, Y.; Schally, Andrew V; Willems, G.

In: International Journal of Cancer, Vol. 52, No. 5, 27.11.1992, p. 791-796.

Research output: Contribution to journalArticle

@article{d6bcf522cc3d411b9ce1e25d40200451,
title = "Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160",
abstract = "Hepatic metastases of colon 320 DM and WidR human colon cancers in nude mice were treated by s.c. injections of somatostatin analogue RC-160 for 4 weeks. Chronic administration of RC-160 significantly inhibited the incidence and growth of liver metastases of these 2 colon-cancer cell lines. After RC-160 treatment, the incidence of liver metastases decreased by 25{\%} for colon 320 DM cells and by 37.5{\%} for WidR cells. The mean number of metastatic tumors in each liver decreased by 47.9{\%} for colon 320 DM and 42.6{\%} for WidR. Survival times of mice with liver tumors of colon 320 DM and WidR cells were prolonged by 20 days and 7 days, respectively. The inhibitory effect of RC-160 on the growth of these 2 colon cancers implanted s.c. was also observed. After administration of RC160 for 4 weeks, the mean tumor volume in the treated groups was only 39.8{\%} of that of controls for the colon 320 DM line and 58{\%} for the WidR line. Tumor-growth rate and final tumor weight were also significantly decreased, while tumor-volume doubling time and tumor-growth delay time were prolonged. The effect of RC-160 on cellular proliferation in the tumors was studied by in vivo labelling with bromodeoxyuridine and immunoperoxidase staining. The mean labelling index in the treatment group was reduced by 14.9{\%} and 19.5{\%}, respectively, for colon 320 DM and WidR tumors. The cytostatic effect of RC-160 was also evident from the apparent reduction in DNA and protein content in the tumor tissues of these cancer lines. Our findings suggest that somatostatin analogue RC-160 may be useful for the treatment of patients with hepatic metastases of colon cancer.",
author = "Y. Qin and Schally, {Andrew V} and G. Willems",
year = "1992",
month = "11",
day = "27",
doi = "10.1002/ijc.2910520520",
language = "English",
volume = "52",
pages = "791--796",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160

AU - Qin, Y.

AU - Schally, Andrew V

AU - Willems, G.

PY - 1992/11/27

Y1 - 1992/11/27

N2 - Hepatic metastases of colon 320 DM and WidR human colon cancers in nude mice were treated by s.c. injections of somatostatin analogue RC-160 for 4 weeks. Chronic administration of RC-160 significantly inhibited the incidence and growth of liver metastases of these 2 colon-cancer cell lines. After RC-160 treatment, the incidence of liver metastases decreased by 25% for colon 320 DM cells and by 37.5% for WidR cells. The mean number of metastatic tumors in each liver decreased by 47.9% for colon 320 DM and 42.6% for WidR. Survival times of mice with liver tumors of colon 320 DM and WidR cells were prolonged by 20 days and 7 days, respectively. The inhibitory effect of RC-160 on the growth of these 2 colon cancers implanted s.c. was also observed. After administration of RC160 for 4 weeks, the mean tumor volume in the treated groups was only 39.8% of that of controls for the colon 320 DM line and 58% for the WidR line. Tumor-growth rate and final tumor weight were also significantly decreased, while tumor-volume doubling time and tumor-growth delay time were prolonged. The effect of RC-160 on cellular proliferation in the tumors was studied by in vivo labelling with bromodeoxyuridine and immunoperoxidase staining. The mean labelling index in the treatment group was reduced by 14.9% and 19.5%, respectively, for colon 320 DM and WidR tumors. The cytostatic effect of RC-160 was also evident from the apparent reduction in DNA and protein content in the tumor tissues of these cancer lines. Our findings suggest that somatostatin analogue RC-160 may be useful for the treatment of patients with hepatic metastases of colon cancer.

AB - Hepatic metastases of colon 320 DM and WidR human colon cancers in nude mice were treated by s.c. injections of somatostatin analogue RC-160 for 4 weeks. Chronic administration of RC-160 significantly inhibited the incidence and growth of liver metastases of these 2 colon-cancer cell lines. After RC-160 treatment, the incidence of liver metastases decreased by 25% for colon 320 DM cells and by 37.5% for WidR cells. The mean number of metastatic tumors in each liver decreased by 47.9% for colon 320 DM and 42.6% for WidR. Survival times of mice with liver tumors of colon 320 DM and WidR cells were prolonged by 20 days and 7 days, respectively. The inhibitory effect of RC-160 on the growth of these 2 colon cancers implanted s.c. was also observed. After administration of RC160 for 4 weeks, the mean tumor volume in the treated groups was only 39.8% of that of controls for the colon 320 DM line and 58% for the WidR line. Tumor-growth rate and final tumor weight were also significantly decreased, while tumor-volume doubling time and tumor-growth delay time were prolonged. The effect of RC-160 on cellular proliferation in the tumors was studied by in vivo labelling with bromodeoxyuridine and immunoperoxidase staining. The mean labelling index in the treatment group was reduced by 14.9% and 19.5%, respectively, for colon 320 DM and WidR tumors. The cytostatic effect of RC-160 was also evident from the apparent reduction in DNA and protein content in the tumor tissues of these cancer lines. Our findings suggest that somatostatin analogue RC-160 may be useful for the treatment of patients with hepatic metastases of colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026496238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026496238&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910520520

DO - 10.1002/ijc.2910520520

M3 - Article

C2 - 1358828

AN - SCOPUS:0026496238

VL - 52

SP - 791

EP - 796

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -